

From: [Tom Heffernan](#)
To: [AGO - High Cost Prescription Drugs](#)
Cc: Jcavallo@gcbiopharmausa.com; [Caitlin Fee](#); [Ryan McGovern](#)
Subject: VT Pharmaceutical Cost Transparency - GC Biopharma USA, Inc. - Alyglo Launch Reporting
Date: Friday, March 22, 2024 12:17:52 PM

Some people who received this message don't often get email from theffernan@federalcompliancesolutions.com.
[Learn why this is important](#)

EXTERNAL SENDER: Do not open attachments or click on links unless you recognize and trust the sender.

Greetings,

On behalf of GC Biopharma USA, Inc., and in compliance with House Bill S 92, please find details of Alyglo's notice of introduction to the market below.

Manufacturer	NDC 11	Drug Name	Commercial Launch Date
GC Biopharma USA, Inc.	61476010405	Alyglo 10% Liquid 5g/50 ml	3/22/2024
GC Biopharma USA, Inc.	61476010410	Alyglo 10% Liquid 10g/100 ml	3/22/2024
GC Biopharma USA, Inc.	61476010420	Alyglo 10% Liquid 20g/200 ml	3/22/2024

Please confirm receipt of this submission and respond with any questions or concerns.

Regards,

Tom Heffernan

Tom Heffernan
Manager

Federal Compliance Solutions LLC
Direct: (484) 767-5327
Email: theffernan@FederalComplianceSolutions.com